Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Macrophage Exclusion after Radiation Therapy (MERT): A First in Human Phase I/II Trial using a CXCR4 Inhibitor in Glioblastoma.

Thomas RP, Nagpal S, Iv M, Soltys SG, Bertrand S, Pelpola JS, Ball RL, Yang J, Sundaram V, Lavezo JL, Born DE, Vogel H, Brown JM, Recht L.

Clin Cancer Res. 2019 Sep 19. pii: clincanres.1421.2019. doi: 10.1158/1078-0432.CCR-19-1421. [Epub ahead of print]

PMID:
31537527
2.

Durable response of glioblastoma to adjuvant therapy consisting of temozolomide and a weekly dose of AMD3100 (plerixafor), a CXCR4 inhibitor, together with lapatinib, metformin and niacinamide.

Rios A, Hsu SH, Blanco A, Buryanek J, Day AL, McGuire MF, Brown RE.

Oncoscience. 2016 Jun 11;3(5-6):156-63. doi: 10.18632/oncoscience.311. eCollection 2016.

3.

Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma.

Lee EQ, Duda DG, Muzikansky A, Gerstner ER, Kuhn JG, Reardon DA, Nayak L, Norden AD, Doherty L, LaFrankie D, Stefanik J, Vardam T, Smith KH, McCluskey C, Gaffey S, Batchelor TT, Jain RK, Wen PY.

Clin Cancer Res. 2018 Oct 1;24(19):4643-4649. doi: 10.1158/1078-0432.CCR-18-1025. Epub 2018 Jun 25.

4.

CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models.

Gravina GL, Mancini A, Muzi P, Ventura L, Biordi L, Ricevuto E, Pompili S, Mattei C, Di Cesare E, Jannini EA, Festuccia C.

Prostate. 2015 Sep;75(12):1227-46. doi: 10.1002/pros.23007. Epub 2015 Jun 12.

PMID:
26073897
5.

Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and Nilotinib.

Dillmann F, Veldwijk MR, Laufs S, Sperandio M, Calandra G, Wenz F, Zeller J, Fruehauf S.

Leuk Lymphoma. 2009 Oct;50(10):1676-86. doi: 10.1080/10428190903150847.

PMID:
19657955
6.

Plerixafor, a CXCR4 antagonist, mitigates skin radiation-induced injury in mice.

Kim JH, Kolozsvary A, Jenrow KA, Brown SL.

Radiat Res. 2012 Sep;178(3):202-6. Epub 2012 Jul 16.

PMID:
22799631
7.

A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03).

Cooper TM, Sison EAR, Baker SD, Li L, Ahmed A, Trippett T, Gore L, Macy ME, Narendran A, August K, Absalon MJ, Boklan J, Pollard J, Magoon D, Brown PA.

Pediatr Blood Cancer. 2017 Aug;64(8). doi: 10.1002/pbc.26414. Epub 2017 Apr 14.

8.

Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.

Pernas S, Martin M, Kaufman PA, Gil-Martin M, Gomez Pardo P, Lopez-Tarruella S, Manso L, Ciruelos E, Perez-Fidalgo JA, Hernando C, Ademuyiwa FO, Weilbaecher K, Mayer I, Pluard TJ, Martinez Garcia M, Vahdat L, Perez-Garcia J, Wach A, Barker D, Fung S, Romagnoli B, Cortes J.

Lancet Oncol. 2018 Jun;19(6):812-824. doi: 10.1016/S1470-2045(18)30147-5. Epub 2018 Apr 26.

PMID:
29706375
9.

Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery.

Green MM, Chao N, Chhabra S, Corbet K, Gasparetto C, Horwitz A, Li Z, Venkata JK, Long G, Mims A, Rizzieri D, Sarantopoulos S, Stuart R, Sung AD, Sullivan KM, Costa L, Horwitz M, Kang Y.

J Hematol Oncol. 2016 Aug 17;9(1):71. doi: 10.1186/s13045-016-0301-2.

10.

Influence of a dual-injection regimen, plerixafor and CXCR4 on in utero hematopoietic stem cell transplantation and engraftment with use of the sheep model.

Goodrich AD, Varain NM, Jeanblanc CM, Colon DM, Kim J, Zanjani ED, Hematti P.

Cytotherapy. 2014 Sep;16(9):1280-93. doi: 10.1016/j.jcyt.2014.05.025.

11.

Phase II radiation therapy oncology group trial of weekly paclitaxel and conventional external beam radiation therapy for supratentorial glioblastoma multiforme.

Langer CJ, Ruffer J, Rhodes H, Paulus R, Murray K, Movsas B, Curran W.

Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):113-9.

PMID:
11516860
12.

Cathepsin K cleavage of SDF-1α inhibits its chemotactic activity towards glioblastoma stem-like cells.

Hira VV, Verbovšek U, Breznik B, Srdič M, Novinec M, Kakar H, Wormer J, der Swaan BV, Lenarčič B, Juliano L, Mehta S, Van Noorden CJ, Lah TT.

Biochim Biophys Acta Mol Cell Res. 2017 Mar;1864(3):594-603. doi: 10.1016/j.bbamcr.2016.12.021. Epub 2016 Dec 28.

13.

Blockade of SDF-1 after irradiation inhibits tumor recurrences of autochthonous brain tumors in rats.

Liu SC, Alomran R, Chernikova SB, Lartey F, Stafford J, Jang T, Merchant M, Zboralski D, Zöllner S, Kruschinski A, Klussmann S, Recht L, Brown JM.

Neuro Oncol. 2014 Jan;16(1):21-8. doi: 10.1093/neuonc/not149. Epub 2013 Dec 10.

14.

Hypofractionated intensity modulated radiotherapy with temozolomide in newly diagnosed glioblastoma multiforme.

Ammirati M, Chotai S, Newton H, Lamki T, Wei L, Grecula J.

J Clin Neurosci. 2014 Apr;21(4):633-7. doi: 10.1016/j.jocn.2013.09.005. Epub 2013 Oct 3.

15.

CXCR4 Expression and Treatment with SDF-1α or Plerixafor Modulate Proliferation and Chemosensitivity of Colon Cancer Cells.

Heckmann D, Maier P, Laufs S, Wenz F, Zeller WJ, Fruehauf S, Allgayer H.

Transl Oncol. 2013 Apr;6(2):124-32. Epub 2013 Apr 1.

16.

Plerixafor induces the rapid and transient release of stromal cell-derived factor-1 alpha from human mesenchymal stromal cells and influences the migration behavior of human hematopoietic progenitor cells.

Wuchter P, Leinweber C, Saffrich R, Hanke M, Eckstein V, Ho AD, Grunze M, Rosenhahn A.

Cell Tissue Res. 2014 Feb;355(2):315-26. doi: 10.1007/s00441-013-1759-7. Epub 2013 Dec 14.

PMID:
24337688
17.

Anti-angiogenic therapy for high-grade glioma.

Ameratunga M, Pavlakis N, Wheeler H, Grant R, Simes J, Khasraw M.

Cochrane Database Syst Rev. 2018 Nov 22;11:CD008218. doi: 10.1002/14651858.CD008218.pub4.

PMID:
30480778
18.

Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.

Brachman DG, Pugh SL, Ashby LS, Thomas TA, Dunbar EM, Narayan S, Robins HI, Bovi JA, Rockhill JK, Won M, Curran WP.

Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):961-7. doi: 10.1016/j.ijrobp.2014.12.050.

19.

Phase II clinical and pharmacologic study of radiation therapy and carboxyamido-triazole (CAI) in adults with newly diagnosed glioblastoma multiforme.

Mikkelsen T, Lush R, Grossman SA, Carson KA, Fisher JD, Alavi JB, Rosenfeld S.

Invest New Drugs. 2007 Jun;25(3):259-63. Epub 2006 Nov 1.

20.

Locoregional Confinement and Major Clinical Benefit of 188Re-Loaded CXCR4-Targeted Nanocarriers in an Orthotopic Human to Mouse Model of Glioblastoma.

Séhédic D, Chourpa I, Tétaud C, Griveau A, Loussouarn C, Avril S, Legendre C, Lepareur N, Wion D, Hindré F, Davodeau F, Garcion E.

Theranostics. 2017 Oct 12;7(18):4517-4536. doi: 10.7150/thno.19403. eCollection 2017.

Supplemental Content

Support Center